Pharmsville Co., Ltd. (KOSDAQ: 318010)
South Korea
· Delayed Price · Currency is KRW 4,700.00
+30.00 (0.64%)
Nov 15, 2024, 9:00 AM KST
Pharmsville Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Net Income | 1,647 | 3,310 | 4,063 | 5,000 | 2,891 | 7,256 | Upgrade
|
| Depreciation & Amortization | 683.4 | 675.99 | 671.39 | 216.32 | 214.54 | 303.98 | Upgrade
|
| Loss (Gain) From Sale of Assets | 33.82 | 33.82 | -41.82 | - | 27.67 | -1,275 | Upgrade
|
| Asset Writedown & Restructuring Costs | 118 | - | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -561.62 | -403.42 | 426.57 | 778.66 | 1,339 | -127.65 | Upgrade
|
| Loss (Gain) on Equity Investments | 63.31 | 63.31 | 32.09 | 24.6 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | -18.73 | 3.29 | - | 27.62 | - | - | Upgrade
|
| Other Operating Activities | -271.49 | 86.72 | -1,284 | 1,282 | -971.65 | 500.6 | Upgrade
|
| Change in Accounts Receivable | 510.07 | 770.44 | 486.7 | -523.8 | 140.43 | -1,091 | Upgrade
|
| Change in Inventory | 73.71 | -243.46 | 1,837 | 847.71 | -2,757 | -974.96 | Upgrade
|
| Change in Accounts Payable | 724.61 | 106.96 | -837.7 | -316.47 | 491.67 | 1,170 | Upgrade
|
| Change in Other Net Operating Assets | 219.17 | 248.13 | -149.61 | 936.23 | -1,307 | -98.17 | Upgrade
|
| Operating Cash Flow | 3,221 | 4,651 | 5,203 | 8,273 | 68.68 | 5,664 | Upgrade
|
| Operating Cash Flow Growth | -43.30% | -10.61% | -37.10% | 11946.19% | -98.79% | 11.61% | Upgrade
|
| Capital Expenditures | -141.01 | -201.48 | -119.79 | -291.03 | -3,527 | -6,589 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 41.82 | - | - | 4,900 | Upgrade
|
| Sale (Purchase) of Intangibles | 8.34 | 1.44 | -24.36 | -34.1 | -20.74 | -255.5 | Upgrade
|
| Investment in Securities | 5,061 | -9,479 | 622.59 | -2,304 | 5,540 | -29,833 | Upgrade
|
| Other Investing Activities | -4.77 | 7.04 | 1 | 29 | 299.6 | - | Upgrade
|
| Investing Cash Flow | 3,923 | -10,672 | 521.26 | -2,600 | 2,292 | -31,778 | Upgrade
|
| Long-Term Debt Issued | - | 55 | 2,377 | 50 | 4,276 | 4,000 | Upgrade
|
| Long-Term Debt Repaid | - | -5,161 | -3,112 | -480.34 | -1,175 | -1,169 | Upgrade
|
| Net Debt Issued (Repaid) | -2,197 | -5,106 | -734.85 | -430.34 | 3,100 | 2,831 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 21,943 | Upgrade
|
| Repurchase of Common Stock | -1,007 | -824.54 | - | - | -998.09 | - | Upgrade
|
| Dividends Paid | -774.99 | -784.64 | -784.64 | -784.64 | -1,586 | -252 | Upgrade
|
| Other Financing Activities | 8.5 | - | - | - | - | -230 | Upgrade
|
| Financing Cash Flow | -3,971 | -6,716 | -1,519 | -1,215 | 516.24 | 24,292 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.33 | -3.89 | -26.54 | 15.67 | -11.22 | 1.18 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | -0 | -0 | - | - | - | Upgrade
|
| Net Cash Flow | 3,176 | -12,740 | 4,179 | 4,474 | 2,865 | -1,821 | Upgrade
|
| Free Cash Flow | 3,080 | 4,450 | 5,083 | 7,982 | -3,459 | -925.39 | Upgrade
|
| Free Cash Flow Growth | -43.99% | -12.46% | -36.31% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 16.18% | 20.80% | 19.47% | 20.45% | -8.78% | -3.09% | Upgrade
|
| Free Cash Flow Per Share | 395.49 | 568.20 | 647.87 | 1017.25 | -439.51 | -139.38 | Upgrade
|
| Cash Interest Paid | 84.06 | 156.35 | 149.21 | 70.62 | 98.9 | 49.68 | Upgrade
|
| Cash Income Tax Paid | 795.23 | 949.59 | 1,718 | 333.14 | 2,272 | 1,691 | Upgrade
|
| Levered Free Cash Flow | 1,509 | 2,264 | 3,680 | 5,535 | -4,592 | -2,326 | Upgrade
|
| Unlevered Free Cash Flow | 1,560 | 2,358 | 3,775 | 5,581 | -4,532 | -2,323 | Upgrade
|
| Change in Net Working Capital | -1,001 | -855.59 | -708.99 | -1,848 | 3,890 | 281.27 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.